Last reviewed · How we verify
CRS-207
CRS-207 is a live, attenuated Listeria monocytogenes vaccine that stimulates an immune response against mesothelin.
CRS-207 is a live, attenuated Listeria monocytogenes vaccine that stimulates an immune response against mesothelin. Used for Mesothelioma.
At a glance
| Generic name | CRS-207 |
|---|---|
| Also known as | Live, attenuated double-deleted Listeria monocytogenes (LADD) |
| Sponsor | Aduro Biotech, Inc. |
| Drug class | vaccine |
| Target | mesothelin |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This vaccine works by infecting cells with a weakened form of Listeria monocytogenes, which then expresses mesothelin on its surface. The immune system recognizes this as foreign and mounts a response against the mesothelin-expressing cells, which are often cancer cells.
Approved indications
- Mesothelioma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Headache
- Chills
- Fever
- Muscle pain
- Joint pain
- Rash
Key clinical trials
- Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer (PHASE2)
- Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer (PHASE2)
- Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer (PHASE2)
- GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab (PHASE2)
- Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma (PHASE1)
- Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) (PHASE2)
- Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer (PHASE1, PHASE2)
- Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CRS-207 CI brief — competitive landscape report
- CRS-207 updates RSS · CI watch RSS
- Aduro Biotech, Inc. portfolio CI